Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC

Hepatocellular Carcinoma Non-Resectable Clinical Trial

— SHINE  

Official title:

Single-arm, Prospective, Multicenter Clinical Trial to Assess the Efficacy and the Safety of Combination Therapy of Hepatic Arterial Infusion of Cisplatin and 5-FU in Advanced Hepatocellular Carcinoma With Low Expression of HMGB2 Biomarker

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02967887
• Other study ID #: CBS-PCT-01
• Status: Recruiting
• Phase: Phase 2
• First received: November 10, 2016
• Last updated: July 13, 2017
• Start date: November 2016
• Est. completion date: December 2018

Study information

• Verified date: July 2017
• Source: CbsBioscience
• Contact: Jin Young Park
• Phone: 82-2-336-0855
• Email: jonnypark[@]cbsbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to assess the efficacy and the safety of hepatic arterial infusion of cisplatin and 5-fluorouracil (HAIC) in advanced HCC patients stratified by biomarker expression predicting therapeutic response.

Description:

Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and 5-fluorouracil has been used in advanced HCC. However, cisplatin or 5-fluorouracil acts on cells without tumor selectivity. Therefore, to improve the tumor selectivity and effectiveness of HAIC, molecular subtyping-based stratification strategies should be considered. In this study, patients who have progressed or intolerance to sorafenib with non-metastatic HCC in TNM stage III-IVA and ECOG PS 0 or 1, Child-Pugh class A will be enrolled. 96 patients with pre-treatment tumor biopsy will receive Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system. This treatment will be repeated every 4 weeks, up to 6 times. The primary objective is to determine overall response rate, where benefit is defined as complete or partial response according to mRECIST V1.1. Secondary endpoints include time to progression, progression free survival. The biopsy tissue will be subjected to real time reverse transcriptase polymerase chain reaction for quantification of gene expression levels. Patients will be categorized into two groups according to gene expression results, and then AUC value of ROC curve analysis will be evaluated as an exploratory endpoint to assess predictive performance of biomarker for therapeutic response of HAIC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 96
• Est. completion date: December 2018
• Est. primary completion date: October 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• over 20 years old

• Patients with advanced hepatocellular carcinoma who have progressed or intolerance to Sorafenib

• Patients with advanced hepatocellular carcinoma who cannot be treated with surgery, transplantation, RFA, or TACE.

• TNM stage III/IV (including intrahepatic single or multiple tumors without extrahepatic metastasis regardless of lymph node metastasis)

• ECOG performance status of 0 or 1

• Liver function status of Child-Pugh Class A or B

• more than 3 months of life expectancy

• serum creatinine <1.5 mg/dL

• aminotransferase <5 times the upper limit of normal

• absolute neutrophil count >1,500 cells/lL

• platelet count >75,000/lL

• hemoglobin >10 g/dL

Exclusion Criteria:

• patients with extrahepatic tumors

• Patients requiring combined treatment with chemotherapy, radiotherapy, TACE, RFA, or others

• Patients in any severe and/or uncontrolled medical conditions

• patients with history of allergic response to CT contrast media

• patients who participated as subjects in other interventional clinical studies (as of the date of visit) within 60 days before drug administration

• Any person deemed inappropriate by reason of the investigator for other reasons

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma Non-Resectable

Intervention

Drug:
• cisplatin and 5-fluorouracil
Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)

Locations

Country	Name	City	State
Korea, Republic of	Korea University Ansan Hospital	Ansan
Korea, Republic of	Sooncheonhyang University Hospital Bucheon	Bucheon
Korea, Republic of	The Catholic University of Korea Bucheon ST. Mary's Hospital	Bucheon
Korea, Republic of	Keimyung University Dongsan Medical Center	Daegu
Korea, Republic of	The Catholic University of Korea Daejeon ST. Mary's Hospital	Daejeon
Korea, Republic of	Chonnam National University Hwasun Hospital	Hwasun
Korea, Republic of	Korea University Anam Hospital	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Sooncheonhyang University Hospital Seoul	Seoul
Korea, Republic of	The Catholic University of korea, Seoul ST. Mary's Hospital	Seoul
Korea, Republic of	Ajou University Hospital	Suwon
Korea, Republic of	The Catholic University of Korea ST. Vincent's Hospital	Suwon

Sponsors (1)

Lead Sponsor	Collaborator
CbsBioscience

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory endpoint: Diagnostic performance of biomarkers	Patients will be categorized according to the result of biomarker expression and then AUC value of ROC curve analysis will be evaluated as an exploratory endpoint to assess predictive performance of biomarkers for therapeutic response of drugs.	Through study completion, an average of 3 months
Primary	Objective tumor response	Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by radiological review	Approximately 6 months
Secondary	Time-to-Progression		Approximately 24 months
Secondary	Progression-free-survival		Approximately 24 months